Vimarsana
Biggest News Aggregation in the World

Page 24 - Iagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iagnostics Today - Breaking & Trending Today

Liquid biopsies could be used as an early marker of immunotherapy response, study finds - Vimarsana News

Liquid biopsies could be used as an early marker of immunotherapy response, study finds

Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells).

CENTOGENE Expands Multiomic Diagnostic Portfolio With - Vimarsana News

CENTOGENE Expands Multiomic Diagnostic Portfolio With

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology...

COVID-19's ripple effect: South African TB diagnostics take a hit - Vimarsana News

COVID-19's ripple effect: South African TB diagnostics take a hit

COVID-19 disrupts TB diagnostic services in South Africa's primary health clinics, highlighting the need for robust systems resilient to future pandemics.

Drug Discovery 2023: A Conversation with Professor Janet Hemingway - Vimarsana News

Drug Discovery 2023: A Conversation with Professor Janet Hemingway

We spoke to Professor Janet Hemingway, founding Director of iiCON and Professor of Tropical Medicine at Liverpool School of Tropical Medicine.

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development - Vimarsana News

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies.